Open Access Highly Accessed Open Badges Research article

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years

Xenofon Baraliakos1*, Hildrun Haibel2, Claudia Fritz3, Joachim Listing3, Frank Heldmann1, Juergen Braun1 and Joachim Sieper2

Author affiliations

1 Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Landgrafenstr. 15, 44652 Herne, Germany

2 Department of Gastroenterology/Rheumatology, Charité, Medical University Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany

3 Epidemiology Department, German Rheumatism Research Center, Schumannstr. 21,10117 Berlin, Germany

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2013, 15:R67  doi:10.1186/ar4244

Published: 20 June 2013



Data from clinical studies on the long-term efficacy and safety of anti-tumor necrosis factor (TNF)-α therapy in patients with ankylosing spondylitis (AS) are scarce. This is the first report on continuous treatment with the TNFα fusion protein etanercept over seven years (y).


Overall, 26 patients with active AS were initially treated with etanercept 2 × 25 mg s.c./week with no concomitant disease modifying anti-rheumatic drugs (DMARDs) or steroids. The clinical response was assessed by standardized parameters. The primary outcome was the proportion of patients in the Spondyloarthritis International Society (ASAS) partial remission at seven years. AS disease activity scores (ASDAS) for status and improvement were compared to conventional outcome measures.


Overall, 21/26 patients (81%) completed two years of treatment and 16/26 patients (62%) completed seven years. In the completer analysis, 31% patients were in ASAS partial remission at seven years, while 44% patients showed an ASDAS inactive disease status. Mean Bath AS activity index (BASDAI) scores, which were elevated at baseline (6.3 ± 0.9), showed constant improvement and remained low: 3.1 ± 2.5 at two years and 2.5 ± 2.2 at seven years, while ASDAS also improved (3.9 ± 0.7 at baseline, 1.8 ± 0.9 at two years, 1.6 ± 0.8 at seven years), all P <0.001. From the 10 dropouts, only 5 patients discontinued treatment due to adverse events. Patients who completed the study had lower baseline Bath AS function index (BASFI) scores vs. patients who discontinued. No other clinical parameter at baseline could predict any long-term outcome.


This study confirms the clinical efficacy and safety of etanercept in patients with active AS over seven years of continuous treatment. After seven years, more than half of the initially treated patients remained on anti-TNF therapy, and one-third were in partial remission.

Trial Registration NCT01289743

ankylosing spondylitis; TNFa; etanercept; ASDAS, BASDAI